Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | CPT1A | P50416 | 1/20 | 0.49 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12172008 | 0.83 | S1PR1 (0.60) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL4876056 | 0.82 | NPC1 (0.56) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL6193033 | 0.81 | HAVCR2 (0.60) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL4875581 | 0.81 | NPC1 (0.54) | NPC1RAB9AL3MBTL1CXCR1S1PR1 | |
| SCHEMBL14072336 | 0.79 | NPC1 (0.61) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL61028 | 0.78 | NPC1 (0.60) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL1430178 | 0.77 | NR1H4 (0.68) | NPC1RAB9AL3MBTL1S1PR1 | |
| SCHEMBL9942403 | 0.77 | HRH3 (0.69) | LTA4HHRH3 | |
| SCHEMBL12171569 | 0.76 | NPC1 (0.76) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL18595108 | 0.75 | HRH3 (0.71) | LTA4HHRH3PSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
| EP-1597243-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | LTA4H 1400/4885NPC1 620/4885RAB9A 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.